ASTRAZENECA AND MAP PHARMACEUTICALS ANNOUNCE WORLDWIDE COLLABORATION TO DEVELOP AND COMMERCIALISE UNIT DOSE BUDESONIDE AstraZeneca and MAP Pharmaceuticals, Inc. announced today an exclusive ...

AstraZeneca and MAP Pharmaceuticals, Inc. announced an exclusive worldwide agreement to develop and commercialize Unit Dose Budesonide (UDB), MAP Pharmaceuticals' proprietary nebulized formulation of ...

AstraZeneca and MAP Pharmaceuticals, Inc. announced today an exclusive worldwide agreement to develop and commercialise Unit Dose Budesonide (UDB), MAP Pharmaceuticals' proprietary nebulised ...

AstraZeneca lifted the veil a bit today on its plans to become a bigger player in emerging markets, saying sales in those those countries will double to account for about a quarter of the British ...

AstraZeneca has terminated its collaboration with the USA’s MAP Pharmaceuticals which involved the development of a potential asthma treatment for children some four months after the drug failed in a ...

AstraZeneca has suffered another clinical disappointment following the news that a late-stage trial by partner MAP Pharmaceuticals looking at a potential asthma treatment for children has fallen by ...

BANGALORE (Reuters) - MAP Pharmaceuticals said it plans to suspend development of its experimental paediatric asthma drug, after its licensing partner AstraZeneca terminated a collaboration on the ...

Gothenburg, Sweden-based Albireo will focus on developing new treatments from a number of early-stage AstraZeneca research programs on gastrointestinal diseases - an area AstraZeneca is moving ...

Achilles Therapeutics plc has announced the transfer of data and samples from its TRACERx Non-Small Cell Lung Cancer study and its Material Acquisition Platform (MAP) to AstraZeneca for a total ...

Dec 19 (Reuters) - Anglo-Swedish drugmaker AstraZeneca Plc said on Friday it signed an agreement to develop and commercialise U.S.-based MAP Pharmaceuticals' pediatric asthma drug. Sign up here.

AstraZeneca and MAP Pharmaceuticals Announce Worldwide Collaboration to Develop and Commercialize Unit Dose Budesonide; AstraZeneca to Pay $40 Million in Cash Upfront LONDON and MOUNTAIN VIEW, Calif.

Under the terms of the agreement, AstraZeneca will pay MAP Pharmaceuticals an upfront cash payment of $40 million and an additional $35 million upon the successful achievement of primary endpoint and ...